Drug Profile

QRX 003

Alternative Names: QRX-003

Latest Information Update: 21 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quoin Pharmaceuticals
Class Anti-inflammatories; Skin disorder therapies; Small molecules
Mechanism of Action Serine protease inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Netherton Syndrome
New Molecular Entity Yes

Highest Development Phases

Phase II/III Netherton Syndrome
Clinical Phase Unknown Peeling skin syndrome
Preclinical Palmoplantar keratoderma

Most Recent Events

07 Aug 2025 Quoin Pharmaceuticals plans a additional trials for other indications in in the coming months (9447608 (9447608)
29 Jul 2025 Quoin Pharmaceuticals announces intention to submit NDA to US FDA for Netherton-Syndrome in second half of 2026
29 Jul 2025 Quoin Pharmaceuticals plans to launch QRX 003 in USA, Europe and Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com